Indian pharmaceutical major Zydus Cadila Friday announced the launch of a new generation drug called Nudoxa for treating various cancers that the company says is a breakthrough in chemotherapy because of its stability and reduced toxicity.
Nudoxa has been patented in India and South Africa. The company has also filed for patents in the European Union, US, Japan and other countries.
Marketed by Zydus Biogen, Nudoxa is manufactured by Zydus-BSV Pharma Pvt Ltd, the joint venture company of Zydus Cadila and Bharat Serums and Vaccines Pvt Ltd.
Founded in 2005, Zydus-BSV Pharma focuses on targeted therapies in the area of oncology (the study of cancer).
Nudoxa would treat various cancers, particularly breast cancer - the second most common type of cancer - and ovarian cancer - the fifth-leading cause of cancer death in women - and AIDS-related Kaposi sarcoma, which develops in people infected with the human immunodeficiency virus (HIV).